Press Room

Contact Information

For media inquiries, please contact our representatives at Landis Communications, Inc.:

Gus Nodal                                Brianne Miller
(415) 359-2320                         (415) 359-2303
gus@landispr.com                   brianne@landispr.com

 


Press Releases

Global Alzheimer’s Platform Foundation Supports $400 Million Congressional Increase for Alzheimer’s Research Funding
Increase is Part of National Institutes of Health (NIH) $2 Billion Funding Boost

WASHINGTON, D.C. (May 4, 2017) – The Global Alzheimer’s Platform Foundation, a nonprofit organization dedicated to expediting Alzheimer’s clinical trials, applauds today’s $400 million Congressional increase in Alzheimer’s research funding. Under the bipartisan vote, the National Institutes of Health (NIH) will receive a $2 billion boost in fiscal year 2017, as it did the previous year. The NIH budget continues to support key areas of research, including Alzheimer’s disease. The new budget sets aside an additional $400 million for Alzheimer’s research for a total of nearly $1.4 billion, a 40 percent increase.

Read the full release here.


Global Alzheimer’s Platform Foundation Appoints Pascale Witz to Board of Directors
Pascale Witz brings two decades of healthcare leadership experience to GAP Board

WASHINGTON, D.C. (Sep. 15, 2016) Global Alzheimer’s Platform Foundation, Inc. (GAP), a nonprofit organization dedicated to reducing the duration, cost and risk of Alzheimer’s clinical trials, today announced the appointment of Pascale Witz to its Board of Directors. In this role, Pascale will provide counsel based on her vast experience working as a healthcare executive with leading healthcare companies. The three-year term commenced on Sep. 1, 2016.

Read the full release here.


Global Alzheimer’s Platform Foundation Announces GAP-Net
First-of-its-Kind Network of Clinical Trial Sites Quickens Timeline and Quality of Alzheimer’s Clinical Trials

WASHINGTON, D.C. (July 28, 2016) – The Global Alzheimer’s Platform Foundation (GAP) announced the launch of GAP-Net, a first-of-its-kind network of clinical trial sites collaboratively working to streamline clinical research and drug development for Alzheimer’s disease. GAP-Net currently has 11 leading academic and private commercial research site partners. The network looks to add a minimum of 20 more sites by year-end and grow to 60 sites nationally by the end of 2017.

Read the full release here.


Global Alzheimer’s Platform Foundation Appoints Dr. Kate Zhong as Chief Strategy Officer
Dr. Zhong Brings More Than 20 Years of Experience to Organization’s New Role

WASHINGTON, D.C. (July 27, 2016) Global Alzheimer’s Platform Foundation (GAP), a nonprofit organization dedicated to reducing the time, cost and risk of Alzheimer’s clinical trials, today announced the appointment of Dr. Kate Zhong to the new position of Chief Strategy Officer (CSO). In this role, Dr. Zhong will lead strategic development advancing GAP’s efforts to disrupt the inefficient clinical trial system with a more patient-centric approach.

Read the full release here.


Majority Of Americans Would Consider Participating In An Alzheimer’s Clinical Trial. So, Why Are Enrollment Numbers So Low?
Global Alzheimer’s Platform (GAP) Foundation is promoting innovative and easier-to-use clinical trial participation tools, including the Brain Health Registry

WASHINGTON, D.C. (July 18, 2016) – In a first-ever poll conducted online by Harris Poll on behalf of the Global Alzheimer’s Platform (GAP) Foundation, nearly 60% of Americans report they are definitely willing or would consider participating in Alzheimer’s disease clinical trials, but participation rates show that less than 10% are actually doing so (source). The failure to provide willing Americans more information and easier-to-use tools for participation could be seen as weakening the attack on America’s most feared disease (source).

Read the full release here.